



UNIVERSITI PUTRA MALAYSIA

**BIOAVAILABILITY AND PHARMACOKINETICS STUDIES OF GAMMA
ORYZANOL**

WAFAA MUSTAFA HASAN HAILAT

FPSK(M) 2004 6

**BIOAVAILABILITY AND PHARMACOKINETICS STUDIES OF GAMMA
ORYZANOL**

By

WAFAA MUSTAFA HASAN HAILAT

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfilment of the Requirements for the Degree of Master of Science**

October 2004



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

BIOAVAILABILITY AND PHARMACOKINETICS STUDIES OF GAMMA ORYZANOL

By

WAFAA MUSTAFA HASAN HAILAT

October 2004

Chairman: Associate Professor Maznah Ismail, Ph.D.

Faculty: Medicine and Health Sciences

Rice bran oil was extracted from rice bran collected after four milling breaks that were used to process rice in Bernas factory, Sekinchan, Malaysia. Two organic solvents were used, a non-polar solvent that was hexane and a mixture of non-polar and polar, which were chloroform-methanol. Gamma oryzanol content of rice bran oil was then quantified, and the total antioxidant activity (TAA) was determined using FTC and TBA methods. After oil extraction, dietary fiber content was quantified in the four phases of defatted rice bran. Results showed that rice bran contained around 20 % lipid in the extracts of the two solvents used. Unlike oil yield, γ -oryzanol content was affected by rice milling and the type of solvent used for extraction. For chloroform-methanol extract, phase 2 of rice milling contained the highest amount of γ -oryzanol (5280 ± 120 ppm), followed by phase 3 (3820 ± 60 ppm), phase 4 (3400 ± 100 ppm), and phase 1 (3000 ± 80 ppm). The four phases of hexane extracts contained lower amount of γ -oryzanol than chloroform-methanol extracts. Phase 2 of rice milling contained the highest γ -oryzanol content (4560 ± 100 ppm), followed by phase 3 (2400 ± 40 ppm), phase 4 (2080 ± 40 ppm), and phase 1 (1600 ± 60 ppm). TAA studies showed that rice

bran oil extracted from phase 2 of rice milling had significantly higher antioxidant activity than phase 1 ($p < 0.05$). However, no significant differences were found among other phases ($p > 0.05$). It was found that rice bran is a good source of dietary fiber. However, fiber distribution was affected also by milling systems. Phase 2 of rice milling contained the highest amount of TDF which was $51.2 \pm 0.9 \%$, followed by phases 3, 1 and 4 that contained $45.2 \pm 1.0 \%$, $37.6 \pm 0.1 \%$ and $35.5 \pm 0.8 \%$ respectively.

Caco-2 cell line was used as *in vitro* model to study γ -oryzanol bioavailability from different formulations that were triolein solution, emulsion, tocotrienol rich fraction (TRF)- γ -oryzanol emulsion, and microspheres. By day 9, cell line showed polarized monolayer properties as was detected from transepithelial electrical resistance (TEER) value ($247.2 \pm 25.0 \Omega\text{cm}^2$) and phenol red diffusion ($4.2 \pm 0.1 \%$). However, all experiments were conducted at day 18, to ensure that cells were fully polarized. *In vitro* digestion of 100 mg dose from each formulation resulted in low micellarization concentrations of γ -oryzanol from both triolein solution and microspheres, that were $21 \pm 2 \mu\text{g/ml}$ digestate, and $20 \pm 2 \mu\text{g/ml}$ respectively. Nevertheless, micellarization concentrations were greatly improved to $5087 \pm 147 \mu\text{g/ml}$ and $5160 \pm 228 \mu\text{g/ml}$, from emulsion and TRF- γ -oryzanol emulsion, respectively. After 10 h of incubation, only $0.43 \pm 0.02 \mu\text{g}$ ($2.03 \pm 0.09 \%$) γ -oryzanol was transported to the lower compartments from triolein solution. Cellular uptake of γ -oryzanol from microspheres after the same period of incubation, increased to $1.25 \pm 0.09 \mu\text{g}$ ($6.33 \pm 0.44 \%$). Gamma oryzanol absorption increased further to $114.94 \pm 2.02 \mu\text{g}$ ($2.31 \pm 0.04 \%$) and $115.82 \pm 4.52 \mu\text{g}$ ($2.24 \pm 0.05 \%$) from emulsion and TRF- γ -oryzanol emulsion, respectively.

Pharmacokinetics of γ -oryzanol was studied using rabbits. Gamma oryzanol emulsion was given as a single intravenous dose. Plasma level of γ -oryzanol was quantified using HPLC. Plasma clearance of γ -oryzanol followed two compartments model, indicating that γ -oryzanol was distributed to the internal tissues. Elimination constant was $0.086 \pm 0.004 \text{ } \mu\text{g/ml.h}$, and the half-life was $8.040 \pm 0.360 \text{ h}$.

Rabbits were used as *in vivo* model to study the bioavailability of γ -oryzanol from triolein solution, microspheres, emulsion and TRF- γ -oryzanol emulsion. The maximum concentration of γ -oryzanol from triolein solution was $6.37 \pm 1.48 \text{ } \mu\text{g/ml}$, and improved to $130.30 \pm 30.40 \text{ } \mu\text{g/ml}$ upon loading γ -oryzanol in microspheres. However, in both formulations, the maximum concentrations were achieved after 2 h of ingestion. Whereas the maximum concentrations of γ -oryzanol from emulsion and TRF- γ -oryzanol emulsion were $555 \pm 100 \text{ } \mu\text{g/ml}$ and $525 \pm 95 \text{ } \mu\text{g/ml}$ respectively and the t_{max} was 2 h.

The absolute bioavailability of γ -oryzanol emulsion was $6.61 \pm 0.86 \%$. The oral emulsion was used as a standard, so that the relative bioavailability (F_{relative}) values of the other formulations were calculated. While F_{relative} for γ -oryzanol from triolein solution was only $0.51 \pm 0.06 \%$, it was significantly ($p < 0.05$) increased to $16.63 \pm 1.71 \%$ upon loading γ -oryzanol in microspheres. Addition of TRF to γ -oryzanol emulsion resulted in an increase of F_{relative} to $109.60 \pm 13.83 \%$. However, this increase could be due to the preservative effect of TRF antioxidants.

In conclusion, the bioavailability of γ -oryzanol was low. However, its absorption increased around 200 times after emulsification and 33 times upon loading in microspheres.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia
sebagai memenuhi keperluan untuk ijazah Master Sains

**KAJIAN BIOAVAILABILITI DAN FARMAKOKINETIK GAMMA
ORIZANOL**

Oleh

WAFAA MUSTAFA HASAN HAILAT

Oktober 2004

Pengerusi: Profesor Madya Maznah Ismail, Ph.D.

Fakulti: Perubatan dan Sains Kesihatan

Minyak dedak beras diekstrak daripada dedak beras yang diperolehi melalui empat peringkat proses pengilangan yang digunakan semasa memproses beras di kilang BERNAS, Sekinchan, Malaysia. Dua pelarut organik telah digunakan, pelarut bukan polar iaitu heksana dan pelarut campuran polar dan bukan polar iaitu kloroform-metanol. Kandungan gamma orizanol bagi minyak dedak beras telah ditentukan dan jumlah aktiviti antioksidan (JAA) telah ditentukan menggunakan kaedah FTC dan TBA. Selepas minyak diekstrak, kandungan fiber diet ditentukan dalam empat fasa dedak beras ternyahlemak. Hasil kajian menunjukkan dedak beras mengandungi lebih kurang 20 % lipid bagi kedua-dua pelarut yang digunakan. Berbeza dengan kandungan minyak, kepekatan orizanol dipengaruhi oleh fasa pengilangan dan jenis pelarut yang digunakan semasa pengekstrakan. Bagi ekstrak kloroform-metanol, fasa kedua proses pengilangan beras menunjukkan amaun γ -orizanol yang tinggi (5280 ± 120 ppm), diikuti fasa ketiga (3820 ± 60 ppm), fasa keempat (3400 ± 100 ppm) dan fasa pertama (3000 ± 80 ppm).

Keempat-empat fasa ekstrak heksana mengandungi peratus γ -orizanol yang lebih rendah daripada ekstrak kloroform-metanol. Bagi ekstrak heksana, sampel daripada fasa kedua proses pengilangan beras menunjukkan peratusan γ -orizanol yang tinggi (4560 ± 100 ppm), diikuti fasa ketiga (2400 ± 40 ppm), fasa keempat (2080 ± 40 ppm) dan fasa pertama (1600 ± 60 ppm). Kajian menunjukkan JAA minyak dedak beras yang diekstrak daripada fasa kedua adalah lebih tinggi secara signifikan daripada fasa pertama ($p < 0.05$). Namun, tiada perbezaan yang signifikan ($p > 0.05$) diperolehi antara fasa-fasa yang lain. Dedak beras merupakan sumber yang baik bagi fiber diet. Walau bagaimanapun taburan fiber turut dipengaruhi oleh sistem pengilangan. Fasa kedua bagi proses pengilangan beras mengandungi amaun jumlah fiber diet (JFD) yang tinggi iaitu 51.2 ± 0.9 %, diikuti fasa ketiga, fasa pertama dan fasa keempat yang mengandungi 45.2 ± 1.0 %, 37.6 ± 0.1 % dan 35.5 ± 0.8 % masing-masing.

Sel Caco-2 digunakan sebagai model *in vitro* untuk mengkaji bioavailabiliti γ -orizanol daripada formulasi yang berbeza, iaitu larutan triolein, emulsi yang kaya dengan pecahan tokotrienol dan mikrosfera. Semasa hari ke-9, titisan sel menunjukkan ciri-ciri ekalapis yang terpolar seperti yang nilai ditunjukkan oleh transepitelial rintangan elektrik (TEER) ($247.2 \pm 25.0 \Omega\text{cm}^2$) dan difusi fenol merah (0.42 ± 0.08 %). Walau bagaimanapun, semua ujikaji yang dijalankan pada hari ke 18 menunjukkan sel-sel berpolar sepenuhnya. Pencernaan *in vitro* bagi dos 100 mg daripada setiap bentuk menunjukkan peratus pemiselan γ -orizanol yang rendah bagi kedua-dua larutan triolein dan mikrosfera, iaitu 21 ± 2 $\mu\text{g/ml}$ dan 20 ± 2 $\mu\text{g/ml}$ penghadaman masing-masing. Namun begitu, kepekatan pemiselan telah meningkat kepada 5087 ± 147 $\mu\text{g/ml}$ dan 5160

$\pm 228 \mu\text{g/ml}$, daripada emulsi dan emulsi yang kaya pecahan tokotrienol masing-masing. Selepas 10 jam eraman, hanya $0.43 \pm 0.02 \mu\text{g}$ ($2.03 \pm 0.09 \%$) γ -orizanol diangkut kepada bahagian yang lebih rendah daripada larutan triolein. Pengambilan selular bagi orizanol daripada mikrosfera selepas tempoh eraman yang sama, meningkat kepada $1.25 \pm 0.09 \mu\text{g}$ ($6.33 \pm 0.44 \%$). Penyerapan γ -orizanol semakin meningkat kepada $114.94 \pm 2.02 \mu\text{g}$ ($2.31 \pm 0.04 \%$) dan $115.82 \pm 4.52 \mu\text{g}$ ($2.24 \pm 0.05 \%$) daripada emulsi dan emulsi yang kaya pecahan tokotrienol masing-masing.

Farmakokinetik bagi γ -orizanol dikaji dengan menggunakan arnab. Emulsi γ -orizanol diberi sebagai dos intravena tunggal. Aras plasma bagi γ -orizanol ditentukan dengan menggunakan HPLC. Pembersihan plasma γ -orizanol mengikuti dua bahagian model, menunjukkan γ -orizanol diagihkan kepada dua tisu dalaman. Pemalar penyingkiran ialah $0.086 \pm 0.004 \mu\text{g/ml.jam}$ dan separuh hayat adalah $8.040 \pm 0.360 \text{ jam}$.

Arnab digunakan sebagai model *in vivo* dalam kajian bioavailabiliti γ -orizanol daripada larutan triolein, mikrosfera, emulsi dan fraksi kaya tokotrienol (FKT) dalam emulsi γ -orizanol. Kepekatan maksimum γ -orizanol daripada larutan triolein ialah $6.37 \pm 1.48 \mu\text{g/ml}$ dan meningkat kepada $130.3 \pm 30.4 \mu\text{g/ml}$ setelah γ -orizanol diberi dalam bentuk mikrosfera. Walau bagaimanapun, dalam kedua-dua bentuk, kepekatan maksimum dicapai selepas 2 jam penghadaman. Kepekatan maksimum γ -orizanol daripada emulsi dan emulsi yang kaya pecahan tokotrienol pula ialah $555 \pm 100 \mu\text{g/ml}$ dan $525 \pm 95 \mu\text{g/ml}$ masing-masing dan masa maksimum bagi kedua-dua bentuk ialah 2 jam.

Bioavailabiliti bagi emulsi γ -orizanol ialah $6.61 \pm 0.86 \%$. Emulsi secara oral digunakan sebagai piawaian, jadi nilai bioavailabiliti relatif (F relatif) bagi setiap bentuk dikira. F (relatif) bagi γ -orizanol daripada larutan triolein hanya $0.51 \pm 0.06 \%$, tetapi ia meningkat secara signifikan ($p < 0.05$) kepada $16.63 \pm 1.71 \%$ apabila γ -orizanol diberi dalam bentuk mikrosfera. Penambahan fraksi kaya tokotrienol (FKT) dalam emulsi orizanol menghasilkan peningkatan F (relatif) kepada $109.60 \pm 13.83 \%$. Walau bagaimanapun, peningkatan ini mungkin akibat daripada kesan pengawetan antioksidan FKT.

Kesimpulannya, bioavailabiliti γ -orizanol adalah rendah. Walau bagaimanapun, penyerapannya meningkat kira-kira 200 kali selepas emulsifikasi dan 33 kali selepas pemberian dalam bentuk mikrosfera.

ACKNOWLEDGEMENTS

I would like to thank my God for shedding on me health and keeping my brain working to the extent of completing this research, which I hope will contribute to the welfare of mankind.

I would like to express my most sincere appreciation to my supervisor Associate Professor Dr. Maznah Ismail for her invaluable attention, guidance, and support throughout my graduate studies. I would like to also thank other members of my committee, Professor Dato' Dr. Abdul Salam Abdullah and Dr. Hishamuddin Omar for their assistance.

I gratefully acknowledge staff, laboratory assistants and graduate students at Department of Nutrition and Health Sciences for their help and cooperation. Finally I would like to convey my appreciation to my parents, husband, brothers and sisters for their support over the course of this thesis.

I certify that an Examination Committee met on 7th October 2004 to conduct the final examination of Wafaa Mustafa Hasan Hailat on her Master of Science thesis entitled “Bioavailability and Pharmacokinetics Studies of Gamma Oryzanol” in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the candidate be awarded the relevant degree. Members of the Examination Committee are as follows:

Hamdan Mohd Noor, Ph.D.

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Muhammad Nazrul Hakim Abdullah, Ph.D.


Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Amsah Haji Yahaya, Ph.D.

Associate Professor
Faculty of Science
Universiti Putra Malaysia
(Member)

Salmijah Surif, Ph.D.

Professor
Faculty of Science and Technology
Universiti Kebangsaan Malaysia
(Independent Examiner)


ZAKARIAH ABD. RASHID, Ph.D.
Professor/Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 20 DEC 2004

This thesis submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee are as follows:

Maznah Ismail, Ph.D.


Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Dato' Abdul Salam Abdullah, Ph.D.

Professor
Faculty of Veterinary Medicine
University Putra Malaysia
(Member)

Hishamuddin Omar, Ph.D.

Faculty of Science and Environmental Studies
University Putra Malaysia
(Member)




AINI IDERIS, Ph.D.
Professor/Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 13 JAN 2005

DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institutions.



WAFAA MUSTAFA HASAN HAILAT

Date: 01 DEC 2004

TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	vi
ACKNOWLEDGEMENTS	x
APPROVAL	xi
DECLARATION	xiii
LIST OF TABLES	xvii
LIST OF FIGURES	xviii
LIST OF ABBREVIATIONS	xx
 CHAPTER	
 1 INTRODUCTION	 1
 2 LITERATURE REVIEW	 6
2.1 Rice Bran	6
2.2 Rice Milling Process	11
2.3 Health Benefits of Rice Bran	11
2.4 Rice Bran Stabilization	12
2.4.1 Chemical Stabilization	13
2.4.2 Physical Stabilization	13
2.4.2.1 Cold Storage	13
2.4.2.2 Storage in An Inert Atmosphere	14
2.4.2.3 Irradiation	14
2.4.2.4 Heat Stabilization	15
2.4.2.4.1 Moist Heat	15
2.4.2.4.2 Dry Heat	16
2.4.2.5 Microwave Stabilisation	17
2.5 Rice Bran Oil	17
2.5.1 Composition of Rice Bran Oil	18
2.5.1.1 Triglycerides	18
2.5.1.2 Minor Constituents	19
2.5.2 Rice Bran Oil Extraction	20
2.5.3 Refining of Crude Oil	20
2.5.4 Health Benefits of Rice Bran Oil	21
2.6 Gamma Oryzanol	22
2.6.1 Overview	22
2.6.2 Biological Effects of γ -Oryzanol	24
2.6.3 Chromatographic Separation of γ -Oryzanol	27
2.6.3.1 Chromatography Principle	27
2.6.3.2 HPLC Principle	28
2.6.3.3 Separation of γ -Oryzanol By HPLC	29



2.7	Bioavailability	33
2.7.1	Estimating The Bioavailability Using <i>In Vivo</i> System	33
2.7.2	Caco-2 Cells: <i>In Vitro</i> System For Estimating Intestinal Absorption	33
2.8	Emulsion As Oral Drug Delivery Form	35
2.9	Microspheres	37
2.9.1	Microspheres As Oral Drug Delivery Form	37
2.9.2	Microspheres Preparation	38
2.10	Kinetics Models of Intravenously Injected Compounds	39
2.10.1	One Compartment Model	39
2.10.2	Two Compartments Model	40
2.10.3	Three Compartments Model	41
3	MATERIALS AND METHODS	42
3.1	Materials	42
3.1.1	Biological Materials	42
3.1.2	Chemicals	43
3.1.3	Instruments and Equipments	43
3.2	Experimental Methods	44
3.2.1	Rice Bran Collection and Stabilization	44
3.2.2	Rice Bran Oil Extraction By Solvent Extraction Method	44
3.2.3	HPLC Analysis of γ -Oryzanol	45
3.2.4	Antioxidant Activity Assay	46
3.2.4.1	Ferric Thiocyanate (FTC) Method	46
3.2.4.2	Thiobarbituric Acid (TBA) Method	47
3.2.5	Total Dietary Fibre Analysis	48
3.2.6	<i>In Vitro</i> Bioavailability Studies of γ -Oryzanol And Its Ferulate Part	49
3.2.6.1	Preparation of γ -Oryzanol Solution	49
3.2.6.2	Preparation of γ -Oryzanol Emulsion	50
3.2.6.3	Preparation of Tocotrienol Rich Fraction (TRF)- γ -Oryzanol Emulsion	50
3.2.6.4	Preparation of γ -Oryzanol Loaded Microspheres	51
3.2.6.5	Cultivation of Caco-2 Cells	52
3.2.6.5.1	Cell Incubation	52
3.2.6.5.2	Transwell Bicameral Chambers	52
3.2.6.5.3	Phenol Red Diffusion	54
3.2.6.5.4	Transepithelial Electrical Resistance (TEER)	54
3.2.6.6	Cellular Uptake Studies	55
3.2.6.6.1	<i>In Vitro</i> Digestion	55
3.2.6.6.2	Cellular Uptake of γ -Oryzanol	56
3.2.6.6.3	Cells Extraction	57
3.2.7	<i>In Vivo</i> Bioavailability and Pharmacokinetics Studies of γ -Oryzanol	58
3.2.7.1	Animals Acclimatization	58
3.2.7.2	Preparation and Administration of Intravenous Dose	58

3.2.7.3 Administration of Oral Doses	59
3.2.7.4 Blood Sampling	59
3.2.7.5 Extraction of γ -Oryzanol From Plasma	60
3.3 Statistical Analysis	61
4 RESULTS AND DISCUSSION	62
4.1 Oil Yield	62
4.2 HPLC Analysis of γ -Oryzanol	65
4.3 Total Antioxidant Activity Studies	72
4.3.1 Ferric Thiocyanate Method	72
4.3.2 Thiobarbituric Acid Method	77
4.4 Fibre Content of Rice Bran	80
4.5 Bioavailability Studies of γ -Oryzanol From Different Formulations Using Caco-2 cells	84
4.5.1 Cell Growth On The Transwell Bicameral Chambers	84
4.5.2 Micellarization of γ -Oryzanol	89
4.5.3 Cellular Uptake of γ -Oryzanol	91
4.5.3.1 Toxicity Test For γ -Oryzanol Formulations	91
4.5.3.2 Cellular Uptake of γ -Oryzanol From Different Formulations	92
4.5.3.2.1 Cellular Uptake of γ -Oryzanol From Triolein Solution	92
4.5.3.2.2 Cellular Uptake of γ -Oryzanol From Emulsion	95
4.5.3.2.3 Cellular Uptake of γ -Oryzanol From TRF- γ -Oryzanol Emulsion	97
4.5.3.2.4 Cellular Uptake of γ -Oryzanol From Microspheres	100
4.6 <i>In Vivo</i> Bioavailability and Pharmacokinetics Studies of γ -Oryzanol	102
4.6.1 Pharmacokinetics of γ -Oryzanol Using Single Dose of Intravenous Emulsion	102
4.6.2 Bioavailability of γ -Oryzanol From Triolein Solution	107
4.6.3 Bioavailability of γ -Oryzanol From Emulsion	110
4.6.4 Bioavailability of γ -Oryzanol From TRF- γ -Oryzanol Emulsion	113
4.6.5 Bioavailability of γ -Oryzanol From Microspheres	115
5 GENERAL DISCUSSION	119
6 CONCLUSION	126
7 RECOMMENDATIONS	128
REFERENCES	129
APPENDICES	141
BIODATA OF THE AUTHOR	155

LIST OF TABLES

Table

2.1	Nutrient composition of stabilized full fat rice bran	9
2.2	Comparison of rice bran to other cereal brans	10
2.3	Composition of crude rice bran oil	18
4.1	Rice bran oil yield from bran at four phases of rice milling breaks using two different solvents	62
4.2	γ - Oryzanol content in rice bran oil extracted from four phases of rice milling process using two different solvents	70
4.3	Percentage of antioxidant activity of rice bran oil extracted from rice bran collected after four milling breaks using FTC method	78
4.4	Percentage of antioxidant activity of rice bran oil extracted from rice bran collected after four milling breaks using TBA method	80
4.5	Dietary fibre contents in rice bran collected from four phases of rice milling	82

LIST OF FIGURES

Figure

2.1	Structure of mature rice grain	7
2.2	Flow chart of rice milling by-products	8
2.3	γ -Oryzanol Structures	23
2.4	HPLC chromatogram of crude rice bran oil	31
2.5	Semilog graph for plasma level-time curve for the compound that follow one compartment model	39
2.6	Semilog graph for plasma level-time curve for the compound that follow two compartments model	40
2.7	Semilog graph for plasma level-time curve for the compound that follow three compartments model	41
3.1	Transwell bicameral chamber, 24 mm diameter	53
4.1	HPLC chromatogram of γ -oryzanol standard	67
4.2	Separation of γ -oryzanol components from crude rice bran oil	68
4.3	HPLC chromatogram of γ -oryzanol extracted from crude rice bran oil	69
4.4	Absorbance values of hexane extracted oil from four phases of rice bran using FTC method	75
4.5	Absorbance values of chloroform-metahnol (2:1) extracted oil from four phases of rice bran using FTC method	76
4.6	Absorbance values of hexane extracted oil from four phases of rice bran using TBA method	79
4.7	Absorbance values of chloroform-metahnol (2:1) extracted oil from four phases of rice bran using TBA method	79
4.8	Phenol red diffusion through transwell bicameral chambers	87
4.9	TEER values across transwell bicameral chambers	88
4.10	Micellarization of γ -oryzanol from different formulations	91

4.11	Cellular uptake of γ -oryzanol from triolein solution	93
4.12	Cellular uptake of ferulic acid	95
4.13	Cellular uptake of γ -oryzanol from emulsion	97
4.14	Cellular uptake of γ -oryzanol from TRF- γ -oryzanol emulsion	99
4.15	Cellular uptake of γ -oryzanol from microspheres	102
4.16	Plasma level of γ -oryzanol after intravenous administration	104
4.17	Logarithm plasma level of γ -oryzanol after the administration of intravenous dose	105
4.18	Elimination phase of γ -oryzanol after the administration of intravenous dose	106
4.19	Plasma level of γ -oryzanol from triolein solution during 72 h	108
4.20	Plasma level of γ -oryzanol from emulsion during 72 h	111
4.21	Plasma level of γ -oryzanol from TRF- γ -oryzanol emulsion during 72 h	113
4.22	Plasma level of γ -oryzanol from microspheres during 72 h	115

LIST OF ABBREVIATIONS

TAA	Total Antioxidant Activity
FTC	Ferric Thiocyanate Method
TBA	Thiobarbituric Acid Method
TRF	Tocotrienol Rich Fraction
TC	Total Cholesterol
HDL-C	High Density Lipoprotein Cholesterol
LDL-C	Low Density Lipoprotein Cholesterol
VLDL-C	Very Low Density Lipoprotein Cholesterol
FFA	Free Fatty Acid
LH	Leuteinizing Hormone
TSH	Thyroid Stimulating Hormone
GH	Growth Hormone
PRL	Prolactin Releasing Hormone
PDA	Photodiode Array
HPLC	High Performance Liquid Chromatography
F	Bioavailability
TDF	Total Dietary Fibre
IDF	Insoluble Dietary Fibre
SDF	Soluble Dietary Fibre
PLGA	Poly (D,L-lactide-co-glycolide)
TEER	Transepithelial Electrical Resistance
DMEM	Dulbecos Modified Eagle Medium
IV	Intravenous

BHT	Butylated Hydroxy Toluene
RBO	Rice Bran Oil



CHAPTER 1

INTRODUCTION

Rice is a staple food for about 60 % of the world population. About 90 % of the world's rice is produced and consumed in Asia. It is second to wheat in terms of annual production. World rice production in 1991 was 466 million metric tonnes (Sayre, 1991), and it has been increasing faster than other grains. For example, by 2002 it increased to 602 million metric tonnes (FAO, 2002). As a result of continuous growth in rice production and consumption, rice research and development activity has become important.

In order to produce edible white rice, it is milled to produce hull, bran, germ, and the white rice. Rice hulls have no nutritional value, but rice bran and germ are rich in protein, lipids, vitamins, and trace minerals (Saunders, 1985). Currently the majority of rice bran is used as animal feed. The naturally occurring enzymatic activity of rice bran leads to the hydrolysis of the oil after milling. However, immediate stabilization of rice bran could convert it to a useful and a healthy product (Ramezanzadeh *et al.*, 1999).

Due to its composition, nutritional profile, functional characteristics and hypoallergenicity, rice bran is added to provide a healthy diet, high in dietary fiber and low in saturated fat (Marshall and Wadsworth, 1994). In addition, Kahlon *et al.* (1990) found that rice bran was as effective as oat bran at lowering serum cholesterol in hypercholesterolemic hamsters. There are strong indications that the consumption of rice bran may be specifically beneficial in reducing the risk of cardiovascular disease, which is now the major cause of mortality in many countries (Marshall and

Wadsworth, 1994; Khor, 1997). The mortality rate has been on the decline since 1960s in countries such as Australia, New Zealand and Japan. However, in Malaysia and China mortality due to cardiovascular disease is increasing and reaching 30-40 % in 1997 (Khor, 1997). Although it had been found that rice bran could protect from cardiovascular diseases, this effect was suggested mainly due to its antioxidants (Marshall and Wadsworth, 1994).

Locally planted rice in Sekinchan is milled through two stage mills to remove first the hulls, and then the bran. However, bran is removed through four millers to produce four phases of rice bran. Few of previous research studied the milling conditions that affect the concentrations of rice bran antioxidants. Most studies focused on the extraction of rice bran oil and the isolation of its antioxidants. Others studied the health benefits of rice bran. Wells (1993) and Martin *et al.* (1993) studied the effect of heat or the stabilization process of rice bran on its tocopherols and tocotrienols levels.

In comparison with other cereal brans, rice bran contains high oil content, which ranged from 16-32 % (Marshall and Wadsworth, 1994). In 1988, only 450,000 metric tonnes of rice bran oil were produced in the world, despite the potential of 2 million metric tonnes. Japan is the leading producer of rice bran oil with an average annual production of 100,000 metric tonnes (Sayre, 1988). Rice bran oil extraction began in Korea using the hydraulic press method. After that hexane extraction was carried out (Sayre, 1988). Supercritical fluid extraction is now investigated as alternative for organic extraction since organic solvents could be hazardous and expensive (Xu and Godber, 2000).

Due to the low content of linolenic acid and high antioxidants content, including tocopherols, tocotrienols, γ -oryzanol and phenolic compounds, rice bran oil has the ability to adjust cholesterol serum level (Marshall and Wadsworth, 1994). Rice bran oil contains 4.2 % of unsaponifiable matter, which is higher than any other common vegetable oils (Sayre, 1991). The unsaponifiable matter comprised mostly of sterols along with γ -oryzanol. Crude rice bran oil can be refined to give a number of beneficial products, including edible rice bran oil, tocopherols and γ -oryzanol.

Gamma oryzanol is a mixture of ferulic acid esters of triterpene alcohols and plant sterols (Rogers *et al.*, 1993). It had been found that crude rice bran oil contains 0.96-2.9 % γ -oryzanol (Marshall and Wadsworth, 1994). Studies proved that γ -oryzanol possesses curative functions for many human diseases, including a reduction of cholesterol level in human and inhibition of platelet aggregation (Seetharamaiah and Chandrasekhara, 1988; Cicero and Gaddi, 2001). In addition, it had been found that γ -oryzanol had the ability to promote skin capillary circulation, and had anti-itching and anti-dandruff action, and has been used in cosmetics (Seetharamaiah and Prabhakar, 1986). However, plant sterols have limited bioavailability. As such, the benefits offered by γ -oryzanol could be limited by its bioavailability.

There are not many studies about the bioavailability and the pharmacokinetics of γ -oryzanol. Fujiwara *et al.* (1983) determined the amount of radioactivity in rat's blood after the administration of radiolabelled γ -oryzanol. The measurement of radioactivity in the blood could lead to overestimation of γ -oryzanol since metabolites could also be detected. Fujiwara *et al.* (1983) reported that 10-20 % of